Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA.
Nat Commun. 2021 May 11;12(1):2633. doi: 10.1038/s41467-021-22867-w.
Ebola virus (EBOV) glycoprotein (GP) can be recognized by neutralizing antibodies (NAbs) and is the main target for vaccine design. Here, we first investigate the contribution of the stalk and heptad repeat 1-C (HR1) regions to GP metastability. Specific stalk and HR1 modifications in a mucin-deleted form (GPΔmuc) increase trimer yield, whereas alterations of HR1 exert a more complex effect on thermostability. Crystal structures are determined to validate two rationally designed GPΔmuc trimers in their unliganded state. We then display a modified GPΔmuc trimer on reengineered protein nanoparticles that encapsulate a layer of locking domains (LD) and a cluster of helper T-cell epitopes. In mice and rabbits, GP trimers and nanoparticles elicit cross-ebolavirus NAbs, as well as non-NAbs that enhance pseudovirus infection. Repertoire sequencing reveals quantitative profiles of vaccine-induced B-cell responses. This study demonstrates a promising vaccine strategy for filoviruses, such as EBOV, based on GP stabilization and nanoparticle display.
埃博拉病毒 (EBOV) 糖蛋白 (GP) 可被中和抗体 (NAb) 识别,是疫苗设计的主要靶点。在这里,我们首先研究了柄部和七肽重复 1-C (HR1) 区域对 GP 亚稳性的贡献。在缺失黏液素的形式 (GPΔmuc) 中对特定柄部和 HR1 进行修饰可提高三聚体产量,而 HR1 的改变对热稳定性则产生更复杂的影响。确定晶体结构可验证两种合理设计的无配体状态下的 GPΔmuc 三聚体。然后,我们在经过重新设计的蛋白纳米颗粒上展示了一种改良的 GPΔmuc 三聚体,该纳米颗粒包含一层锁定结构域 (LD) 和一簇辅助 T 细胞表位簇。在小鼠和兔子中,GP 三聚体和纳米颗粒可引发针对埃博拉病毒等埃博拉病毒的交叉 NAb,以及增强假病毒感染的非 NAb。受体序列分析揭示了疫苗诱导 B 细胞反应的定量特征。这项研究基于 GP 稳定化和纳米颗粒展示,为埃博拉病毒等丝状病毒展示了一种有前途的疫苗策略。